Zacks Investment Research upgraded shares of IsoRay (NYSEAMERICAN:ISR) from a sell rating to a hold rating in a report published on Thursday.
According to Zacks, “IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company’s Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated. “
A number of other research analysts have also commented on the stock. HC Wainwright set a $1.00 price objective on shares of IsoRay and gave the company a hold rating in a research note on Tuesday, November 13th. Maxim Group lowered shares of IsoRay from a buy rating to a hold rating in a research note on Friday, November 9th.
IsoRay (NYSEAMERICAN:ISR) last posted its quarterly earnings data on Thursday, November 8th. The healthcare company reported ($0.02) EPS for the quarter, meeting analysts’ consensus estimates of ($0.02). The business had revenue of $1.56 million during the quarter, compared to analyst estimates of $1.73 million.
In other news, CEO Lori A. Woods bought 130,000 shares of the stock in a transaction dated Thursday, November 15th. The shares were acquired at an average price of $0.40 per share, with a total value of $52,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 125,000 shares in the company, valued at $50,000. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders acquired 176,735 shares of company stock worth $71,619.
An institutional investor recently raised its position in IsoRay stock. Vanguard Group Inc. grew its position in IsoRay, Inc. (NYSEAMERICAN:ISR) by 24.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,857,268 shares of the healthcare company’s stock after acquiring an additional 367,324 shares during the period. Vanguard Group Inc. owned about 2.76% of IsoRay worth $964,000 at the end of the most recent quarter.
IsoRay Company Profile
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
Featured Story: Technical Analysis of Stocks and What It Means
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.